Talk:Allosteric regulation

message: I thought allosteric meant regulation as a result of induced structural changes.
:That's not the best definition for it, but it does include structural changes. Richard001 07:31, 2 August 2007 (UTC)
thread_title: Meaning

message: I didn't nominate the first one, but I suggest we merge both. Richard001 07:33, 2 August 2007 (UTC)
replies: text: I agree. Homotropic allosteric modulator should also be merged into this article. Fuzzform 02:29, 22 October 2007 (UTC)
thread_title: Merge

message: I'm a reasonably intelligent person (earned a college scholarship in engineering), yet couldn't understand this article.  You basically have to have studied medicine for this to make sense.  For example, look at this sentence at the start of the Pharmacology section :
"Allosteric modulation of a receptor results from the binding of allosteric modulators at a different site (regulatory site) other than of the endogenous ligand (orthosteric ligand) and enhances or inhibits the effects of the endogenous ligand."
I don't recognize the following terms:
:Allosteric modulation
:Regulatory site
:Endogenous ligand
:Orthosteric ligand
Aren't there any ENGLISH words that can be used to describe this process ?  If a few unknown words are used I could look them up, but with this many in one sentence (and the strong possibility that looking any of them up in Wikipedia will produce even more confusing terms), I can't see how I can understand such a sentence without first going to medical school.  Also, this subject seems just made for illustrations.  Aren't there any available ? 68.74.2.210 (talk) 13:49, 30 August 2008 (UTC)
thread_title:  Article needs simplification 

message: I propose that Positive allosteric modulator & Negative allosteric modulator be merged into Allosteric modulation. These two articles say essentially the same thing. I think that the content in both the positive and neagative articles can easily be explained in the context of allosteric modulation, and the Allosteric regulation article is of a reasonable size in which the merging will not cause any problems as far as article size or undue weight is concerned. Andrewaskew (talk) 00:43, 15 June 2012 (UTC)
replies: text: This sounds like an excellent idea to me. I'd be even happier if we could pull together an overall article "Allostery", perhaps with several child articles. Dcrjsr (talk) 16:31, 4 July 2012 (UTC)
thread_title:  Merger proposal 

message: It's good to include the AlloStery Database.  But I've edited to fix typos, make it a more appropriate length and less repetitive with the next section, and especially to achieve NPOV.  Many of the claims could still use some references (such as for whether allosteric effectors are really more specific and therefore less toxic than other drugs).  I also agree with the complaint that this article is not very clearly explained and feel it is definitely confusing between single-chain allostery and multi-subunit allostery.  I'll try to come back to it later when I get a chance, since I think it's a very important topic. Dcrjsr (talk) 01:52, 16 August 2012 (UTC)
replies: text: Thank you for your efforts. I was just looking at this article because of this blog post. I find the article fairly technical and I have a difficult time understanding this article, most likely because I'm not a protein biochemist. I think it could be simplified or clarified, but I don't understand allostery in the first place! • Jesse V.(talk) 23:49, 19 August 2012 (UTC)
thread_title:  NPOV and clarity 

message: Substituted at 07:25, 29 April 2016 (UTC)
thread_title: Assessment comment

message: The article Obligate activator is based on low-quality sources (USMLE test study guide) and is inaccurate. The information stated there does not appear in any other source context other than quoting from the same place. Essential, or "obligate" activators, are just a form of allosteric activators, which only refers to the mechanism in which they function (making conformational changes in an enzyme to increase its affinity).
Here source describing N-acetyl-glutamate (mentioned as an example in the article) as an allosteric activator:
"Physical location of the site for N-acetyl-L-glutamate, the allosteric activator of carbamoyl phosphate synthetase, in the 20-kilodalton COOH-terminal domain."
Therefore, I am correcting that article and merging to here. Ibenami (talk) 23:57, 16 January 2018 (UTC)
thread_title:  Merging "Obligate activator" to here 

message: Sections 'Allosteric modulation', 'Energy sensing model', and 'Pharmacology' contain much duplicated material. I recommend that these be unified: the single section could be titled 'Allosteric modulation' with the current 'Allosteric modulation' content pruned a little and used as the intro. parag.  Its five subsections could be 'Positive modulation', 'Negative modulation', 'Pharmacology', 'Allosteric sites as drug targets', and 'Allosteric sites as Energy sensing mechanisms'.
Putting these under one section should make elimination of redundant material easier.  The to-be last subsection taken from the current 'Energy sensing model' is the only place where i would add material since the current intro parag there doesn't make a suitable connection between allostery and sensing. Sbrozell0 (talk) 00:42, 6 July 2018 (UTC)
thread_title:  Combine sections 2, 3 , and 6. 

message: I propose to merge Allosteric modulator into Allosteric regulation.
I think that the content in the Allosteric modulator article, which is essentially from a pharmacological perspective, can easily be explained in the context of Allosteric regulation, from a broader biochemical perspective, and that the Allosteric regulation article is of a reasonable size that the merging of Allosteric regulation will not cause any problems as far as article size is concerned. Jamgoodman (talk) 12:15, 28 May 2019 (UTC)
thread_title:  Merger proposal